Clinical Scorecard: Multicenter Evaluation of Long-term Clinical Outcomes Following Digital Deep Brain Stimulation in Real-world Settings

At a Glance

Key Highlights

• Remote DBS programming accelerates clinical improvement without compromising safety or patient satisfaction in the initial 3 months.
• Sustained clinical benefits and similar improvements in outcomes, quality of life, and safety observed at 6 and 12 months across remote and in-clinic care groups.
• Remote programming implemented as a complementary option to in-clinic care, supporting scalability and ecological validity in real-world settings.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of Parkinson’s disease requiring DBS should be confirmed prior to implantation and programming.

Management

• Initial DBS programming should be conducted in-clinic with subsequent titration visits conducted either remotely via virtual clinic or in-clinic.
• Remote DBS programming can be integrated as a complementary option alongside routine in-clinic visits.
• Multidisciplinary management including pharmacological adjustments and treatment of non-motor symptoms remains essential.

Monitoring & Follow-up

• Long-term follow-up visits recommended at 6 and 12 months post-initial programming, with flexibility for remote or in-clinic visits based on patient and physician preference.
• Patient- and clinician-reported global improvement and symptom severity should be regularly assessed.
• Quality of life and motor function assessments (e.g., PDQ-39, MDS-UPDRS Part III) should be incorporated into follow-up evaluations.

Risks

• No significant safety concerns identified with remote DBS programming compared to in-clinic care.
• Continued access to multidisciplinary in-clinic care is necessary to address complex patient needs beyond DBS programming.

Patient & Prescribing Data

Patients with advanced Parkinson’s disease undergoing DBS therapy

Remote programming showed a trend toward reduction in levodopa equivalent dose, while in-clinic group showed slight increase; variability was high and overlapping between groups.

Clinical Best Practices

• Use a hybrid care model combining in-clinic initial programming with flexible remote or in-clinic titration visits.
• Ensure patient and clinician choice in selecting remote versus in-clinic follow-up to optimize engagement and outcomes.
• Incorporate standardized patient- and clinician-reported outcome measures to monitor global improvement and symptom severity longitudinally.
• Maintain routine multidisciplinary in-clinic visits every 6 to 12 months to manage pharmacological and non-motor aspects of Parkinson’s disease.
• Leverage digital health platforms to expand access and personalize DBS programming while preserving safety and patient satisfaction.

References

• Study reporting initial 3-month RCT results on remote DBS programming